Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

  • Technology appraisal guidance
  • TA308
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the committee

The evidence review group (ERG) report for this appraisal was prepared by the School of Health and Related Research (ScHARR), University of Sheffield:

  • Latimer N et al. Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis, May 2013

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers or sponsors were also invited to make written submissions. Professional or specialist and patient or carer groups, and other consultees, had the opportunity to give their expert views. Manufacturers or sponsors, Professional or specialist and patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • Roche Products

Professional or specialist and patient or carer groups:

  • Vasculitis UK

  • British Association of Dermatologists

  • British Association for Paediatric Nephrology

  • British Society for Rheumatology

  • British Society for Paediatric and Adolescent Rheumatology

  • British Thoracic Society

  • Primary Care Rheumatology Society

  • Renal Association

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

Other consultees:

  • Department of Health

  • Bournemouth and Poole, and Dorset PCT Cluster

  • Welsh Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Pfizer

  • Arthritis Research UK

  • Vasculitis Rare Disease Working Group of the UK and Ireland

  • School of Health and Related Research (ScHARR)

  • National Institute for Health Research Health Technology Assessment Programme

The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on rituximab in combination with glucocorticoids by attending the committee discussion and providing written evidence to the committee. They were also invited to comment on the ACD.

  • Professor Lorraine Harper, Professor of Nephrology, nominated by the Renal Association – clinical specialist

  • Dr Peter Lanyon, nominated by the British Society for Rheumatology – clinical specialist

  • John Mills, nominated by Vasculitis UK – patient expert

  • Lisa Ranyell, nominated by Vasculitis UK – patient expert

Representatives from the following manufacturer or sponsor attended committee meetings. They contributed only when asked by the committee chair to clarify specific issues and comment on factual accuracy.

  • Roche Products

ISBN: 978-1-4731-0500-3